LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $1,901 | $5,605 | $8,507 | $18,166 |
| - Cash | $28 | $246 | $370 | $271 |
| + Debt | $414 | $424 | $499 | $381 |
| Enterprise Value | $2,287 | $5,783 | $8,635 | $18,276 |
| Revenue | $615 | $573 | $687 | $503 |
| % Growth | 7.2% | -16.6% | 36.6% | – |
| Gross Profit | $507 | $456 | $534 | $381 |
| % Margin | 82.5% | 79.5% | 77.7% | 75.9% |
| EBITDA | -$49 | -$369 | -$77 | -$67 |
| % Margin | -7.9% | -64.3% | -11.2% | -13.4% |
| Net Income | -$100 | -$433 | -$145 | -$237 |
| % Margin | -16.3% | -75.6% | -21.2% | -47.1% |
| EPS Diluted | -0.94 | -4.05 | -1.88 | -0.019 |
| % Growth | 76.8% | -115.4% | -10,062.2% | – |
| Operating Cash Flow | -$121 | -$295 | -$182 | -$1 |
| Capital Expenditures | -$18 | -$44 | -$57 | -$299 |
| Free Cash Flow | -$139 | -$339 | -$240 | -$300 |